PURPOSE: To investigate the ability of the EQ-5D to discriminate between levels of alcohol risk in a large sample of hazardous and harmful drinkers, and to explore the relationship between transitions between alcohol risk levels and changes in EQ-5D up to 12 months. METHODS: This is a web-based randomised controlled trial evaluating a novel intervention for hazardous and harmful alcohol consumption. EQ-5D scores were compared among groups of drinkers at baseline (low/medium/high risk according to self-reported past week alcohol consumption), and changes in EQ-5D scores were estimated as a function of changes in alcohol consumption level. RESULTS: Baseline EQ-5D scores were dominated by problems with anxiety/depression, which increased with alcohol risk level, whilst high-risk drinkers also experienced more problems with physical HRQoL dimensions. However, the tool demonstrated a considerable ceiling effect. At follow-up, despite considerable reductions in alcohol consumption across the sample, significant changes in aggregated EQ-5D index scores were only observed for high-risk drinkers at baseline who reduced their drinking, with small improvements (0.04-0.06) compared to those who did not reduce. CONCLUSIONS: Our results suggest that the three-option EQ-5D may not be an optimal primary end point for measuring clinical and cost-effectiveness in randomised controlled trials of interventions among hazardous and harmful alcohol users, although further testing of the sensitivity of the tool in these populations is needed.
PURPOSE: To investigate the ability of the EQ-5D to discriminate between levels of alcohol risk in a large sample of hazardous and harmful drinkers, and to explore the relationship between transitions between alcohol risk levels and changes in EQ-5D up to 12 months. METHODS: This is a web-based randomised controlled trial evaluating a novel intervention for hazardous and harmful alcohol consumption. EQ-5D scores were compared among groups of drinkers at baseline (low/medium/high risk according to self-reported past week alcohol consumption), and changes in EQ-5D scores were estimated as a function of changes in alcohol consumption level. RESULTS: Baseline EQ-5D scores were dominated by problems with anxiety/depression, which increased with alcohol risk level, whilst high-risk drinkers also experienced more problems with physical HRQoL dimensions. However, the tool demonstrated a considerable ceiling effect. At follow-up, despite considerable reductions in alcohol consumption across the sample, significant changes in aggregated EQ-5D index scores were only observed for high-risk drinkers at baseline who reduced their drinking, with small improvements (0.04-0.06) compared to those who did not reduce. CONCLUSIONS: Our results suggest that the three-option EQ-5D may not be an optimal primary end point for measuring clinical and cost-effectiveness in randomised controlled trials of interventions among hazardous and harmful alcohol users, although further testing of the sensitivity of the tool in these populations is needed.
Authors: Jonathan A C Sterne; Ian R White; John B Carlin; Michael Spratt; Patrick Royston; Michael G Kenward; Angela M Wood; James R Carpenter Journal: BMJ Date: 2009-06-29
Authors: Samuli I Saarni; Kaisla Joutsenniemi; Seppo Koskinen; Jaana Suvisaari; Sami Pirkola; Harri Sintonen; Kari Poikolainen; Jouko Lönnqvist Journal: Alcohol Alcohol Date: 2008-02-01 Impact factor: 2.826
Authors: Elizabeth Murray; Jim McCambridge; Zarnie Khadjesari; Ian R White; Simon G Thompson; Christine Godfrey; Stuart Linke; Paul Wallace Journal: BMC Public Health Date: 2007-10-26 Impact factor: 3.295
Authors: Edimansyah Abdin; Mythily Subramaniam; Janhavi Ajit Vaingankar; Nan Luo; Siow Ann Chong Journal: Qual Life Res Date: 2014-11-14 Impact factor: 4.147
Authors: Eve Wittenberg; Carolina Barbosa; Riley Hein; Emma Hudson; Benjamin Thornburg; Jeremy W Bray Journal: Drug Alcohol Depend Date: 2021-01-29 Impact factor: 4.492
Authors: Eileen Fs Kaner; Fiona R Beyer; Claire Garnett; David Crane; Jamie Brown; Colin Muirhead; James Redmore; Amy O'Donnell; James J Newham; Frank de Vocht; Matthew Hickman; Heather Brown; Gregory Maniatopoulos; Susan Michie Journal: Cochrane Database Syst Rev Date: 2017-09-25
Authors: Abhijit Nadkarni; Benedict Weobong; Helen A Weiss; Jim McCambridge; Bhargav Bhat; Basavaraj Katti; Pratima Murthy; Michael King; David McDaid; A-La Park; G Terence Wilson; Betty Kirkwood; Christopher G Fairburn; Richard Velleman; Vikram Patel Journal: Lancet Date: 2016-12-15 Impact factor: 79.321